Curaleaf (OTCMKTS:CURLF – Get Free Report) and Stryker (NYSE:SYK – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Volatility & Risk
Curaleaf has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.
Insider and Institutional Ownership
0.0% of Curaleaf shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Curaleaf | -2.62% | -0.88% | -0.26% |
| Stryker | 14.43% | 23.63% | 11.39% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Curaleaf and Stryker, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Curaleaf | 0 | 0 | 2 | 3 | 3.60 |
| Stryker | 0 | 5 | 18 | 0 | 2.78 |
Stryker has a consensus target price of $374.42, suggesting a potential upside of 37.60%. Given Stryker’s higher possible upside, analysts clearly believe Stryker is more favorable than Curaleaf.
Earnings and Valuation
This table compares Curaleaf and Stryker”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Curaleaf | $1.27 billion | 2.04 | -$231.07 million | ($0.13) | -85.15 |
| Stryker | $25.12 billion | 4.16 | $3.25 billion | $9.65 | 28.20 |
Stryker has higher revenue and earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.
Summary
Stryker beats Curaleaf on 12 of the 15 factors compared between the two stocks.
About Curaleaf
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
About Stryker
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
